When bone marrow stops working, the body becomes a house without a foundation.
When the body's own marrow turns against itself, the consequences unfold with quiet devastation — infections, uncontrolled bleeding, and a profound exhaustion that signals something foundational has failed. This week, the American Society of Hematology released updated clinical guidelines for severe acquired aplastic anemia, a rare but widely underrecognized bone marrow failure disorder affecting millions each year across the globe. The 33 recommendations, built on multidisciplinary consensus and patient input, seek to close the gap between what medicine knows and what patients actually receive — from sharper diagnostics to more personalized, evidence-guided treatment.
- Severe aplastic anemia quietly claims between one and seven million patients annually depending on region, yet remains widely overlooked by clinicians who may not recognize its warning signs in time.
- Without enough neutrophils, platelets, or red blood cells, patients face a cascade of life-threatening crises — septic infections, unstoppable bleeding, and exhaustion so deep it signals systemic collapse.
- The new ASH guidelines push for expanded genetic and blood-based diagnostics to ensure patients are correctly identified and routed to appropriate care before the disease outpaces treatment options.
- Adding eltrombopag to standard immunosuppressive therapy marks a meaningful shift in first-line treatment, with evidence suggesting improved blood cell recovery in both children and adults.
- For patients who relapse or fail initial therapy, the guidelines chart a clearer path to second-line interventions — reducing the dangerous drift that can occur when clinicians lack structured guidance.
- Shared decision-making and calls for expanded global access to transplant therapies signal that these guidelines are as much about equity and patient dignity as they are about clinical protocol.
When bone marrow stops producing blood cells, the body loses its most essential infrastructure. The American Society of Hematology this week published updated clinical guidelines for severe acquired aplastic anemia — a rare immune-mediated disorder in which the marrow fails, leaving patients exposed to septic infections, uncontrolled bleeding, and profound fatigue. The guidelines, appearing in Blood Advances, were developed by a multidisciplinary panel that included a patient living with the disease.
The disorder is more common than most realize. Western countries see one to two million cases annually; in Asia, that figure rises to five or seven million. Most cases are immune-mediated or idiopathic, though infections, medications, and toxic exposures can also trigger the disease. Severe cases are defined by dangerously low counts of neutrophils, platelets, and immature red blood cells — thresholds that mark the line between serious illness and life-threatening crisis.
The 33 recommendations call for expanded diagnostic testing, including genetic analysis, to confirm diagnoses quickly and accurately. Treatment is to be personalized based on patient age and donor availability. Notably, the guidelines recommend adding eltrombopag — a drug that stimulates blood cell production — to standard immunosuppressive therapy, a combination showing improved outcomes in both adults and children. For those who relapse or don't respond, a clearer roadmap to second-line therapies is now in place.
Committee chair Phil Scheinberg stressed that accurate diagnosis is the foundation of everything that follows, while ASH president Robert Negrin described the guidelines as a long-overdue resource for clinicians. Beyond treatment, the guidelines call for shared decision-making and flag a persistent gap: the need for more research and broader global access to transplantation and immunosuppressive therapies — because for a disease that can be fatal when left untreated, the best evidence available must reach every patient who needs it.
When bone marrow stops working, the body becomes a house without a foundation. The American Society of Hematology released updated clinical guidelines this week for diagnosing and treating severe acquired aplastic anemia, a rare disorder in which the marrow fails to produce enough blood cells. The result is a cascade of vulnerability: profound fatigue, infections that can turn septic within hours, bleeding that won't stop. The guidelines, published in Blood Advances, represent the consensus of a multidisciplinary panel that included a patient living with the disease.
The scale of the problem is larger than most people realize. Between one and two million people develop aplastic anemia each year in Western countries. In Asia, the numbers climb to five or seven million annually. Most cases are immune-mediated—the body's own immune system attacking bone marrow cells—or idiopathic, meaning doctors cannot identify a cause. But acquired aplastic anemia can also be triggered by infections, medications, toxic exposures, or chemicals. The severe form of the disease is defined by specific blood counts: fewer than 500 neutrophils per microliter (the white blood cells that fight infection), fewer than 60,000 reticulocytes per microliter (immature red blood cells), and fewer than 20,000 platelets per microliter (cells essential for clotting).
The new guidelines contain 33 distinct recommendations and four good practice statements aimed at improving outcomes for both children and adults. They call for expanded use of advanced diagnostic testing—specialized blood work and genetic analysis—to confirm the diagnosis and guide treatment decisions. This matters because getting the diagnosis right means getting patients to the right treatment quickly. The recommendations also emphasize personalized initial treatment based on a patient's age and whether a fully matched bone marrow donor is available. For many patients, the guidelines recommend adding eltrombopag, a drug that stimulates blood cell production, to standard immunosuppressive therapy. This combination has shown promise in improving blood cell counts in both adults and children. For patients who do not respond to initial treatment or who relapse, the guidelines provide a roadmap for earlier transition to second-line therapies.
Phil Scheinberg, chair of the ASH guidelines committee and head of hematology at Hospital Beneficência Portuguesa in São Paulo, emphasized that accurate diagnosis is the foundation of everything that follows. "It's critical to definitively diagnose individuals with aplastic anemia to ensure that they are promptly connected to appropriate treatment," he said. The guidelines also stress the importance of shared decision-making between patients and their doctors—a recognition that treatment choices involve trade-offs and that patients deserve a voice in those decisions.
Robert Negrin, ASH president, called the guidelines "a robust and much-needed resource" for clinicians. Aplastic anemia remains an overlooked disorder despite its severity, and these recommendations aim to raise awareness among physicians who might otherwise miss or delay diagnosis. The guidelines also highlight a critical gap: the need for more research to develop higher-certainty recommendations and to expand global access to bone marrow transplantation and immunosuppressive therapies. For now, these 33 recommendations represent the best evidence available to guide care for a disease that, left untreated, can be fatal.
Citas Notables
It's critical to definitively diagnose individuals with aplastic anemia to ensure that they are promptly connected to appropriate treatment.— Phil Scheinberg, chair of ASH guidelines committee
These guidelines offer important consensus for the field while helping raise awareness of a serious yet often overlooked disorder.— Robert Negrin, ASH president
La Conversación del Hearth Otra perspectiva de la historia
Why does bone marrow stop working in the first place? Is it always the same mechanism?
No. Sometimes the immune system mistakenly attacks the marrow cells—that's the immune-mediated form. Other times there's no clear cause at all. But acquired aplastic anemia can also follow an infection, a medication, or exposure to something toxic. The body's response varies, which is why diagnosis matters so much.
So if someone has fewer than 500 neutrophils per microliter, they're essentially defenseless against infection?
Essentially, yes. A healthy person has thousands. At that level, a minor cut or a routine bacterial exposure becomes dangerous. The body can't mount an effective immune response. That's why these patients need careful monitoring and often prophylactic antibiotics.
The guidelines mention eltrombopag. What does that drug actually do?
It signals the bone marrow to produce more blood cells. It's not a cure—it doesn't fix the underlying problem—but it can boost counts enough to reduce the immediate risk of bleeding and infection while other treatments work.
Why include a patient on the guideline panel?
Because clinicians can miss things that matter most to people living with the disease. A patient knows what it feels like to wait for test results, to weigh the side effects of treatment against the risk of doing nothing. That perspective shapes better recommendations.
The guidelines mention higher incidence in Asia. Why?
That's not entirely clear. There may be genetic factors, environmental exposures, or differences in how the disease is diagnosed and reported. But the disparity is real and significant—five to seven million cases per year compared to one to two million in the West.
What happens to someone who doesn't respond to the initial treatment?
That's where the guidelines provide a roadmap for moving to second-line therapies sooner rather than later. The goal is to avoid prolonging a treatment that isn't working while the patient's counts stay dangerously low.